Serious adverse events reported for antiobesity medicines: postmarketing experiences from the EU adverse event reporting system EudraVigilance
Crossref DOI link: https://doi.org/10.1038/ijo.2016.135
Published Online: 2016-08-01
Published Print: 2016-11
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Aagaard, L
Hallgreen, C E
Hansen, E H
Text and Data Mining valid from 2016-08-01
Version of Record valid from 2016-08-01
Article History
Received: 7 June 2016
Revised: 4 July 2016
Accepted: 12 July 2016
First Online: 1 August 2016
Competing interests
: The authors declare no conflict of interest.